CEACAM20 Antibody (1032339) [Alexa Fluor® 350]

• Applications: Flow
• Clone: 1032339
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 350

CEACAM20 Antibody (1032339) [Alexa Fluor® 350] Summary

• Immunogen: Human embryonic kidney cell HEK293-derived human CEACAM-20
  Gln31-Gly450
  Accession # Q6UY09-1
• Specificity: Detects human CEACAM-20 in direct ELISAs.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze.
  • 12 months from date of receipt, 2 to 8 °C as supplied.
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.
• Reconstitution Instructions: Reconstitution default not known

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Background

Carcinoembryonic antigen-related cell adhesion molecule-20 (CEACAM-20) is a member of the CEACAM subfamily of glycoproteins in the immunoglobulin (Ig) superfamily. Mature human CEACAM-20 consists of a 420 amino acid (aa) extracellular domain (ECD), a 21 aa helical transmembrane segment, and a 114 aa cytoplasmic domain. The extracellular domain possesses four IgC2-like domains which are stabilized by disulfide bonds, as well as several predicted glycosylation sites (1-5). The extracellular domain of CEACAM-20 is also unique among the CEACAMs because it contains a truncated IgV-like N domain (2). Within the ECD, human CEACAM-20 shares 64% and 62% aa identity with the mouse and rat CEACAM-20, respectively. The cytoplasmic domain is unusually long compared to most other CEACAMs and is predicted to contain four tyrosine phosphorylation sites, two of which correspond to the immune-receptor tyrosine-based activation motif (ITAM) (2, 3). Human CEACAM proteins have been linked to numerous intercellular-adhesion and intracellular signaling processes including cell adhesion, growth, and recognition, differentiation, angiogenesis, and apoptosis (7, 8). Human CEACAM-20 expression is limited to the reproductive system and the intestinal tract, with the highest levels of expression found in the small intestine and prostate (2, 3). An in vitro model of human prostate morphogenesis showed that CEACAM-20 is co-expressed with CEACAM-1 and plays a critical role in the formation of prostate organoids, making it a marker for prostate cancer (2). Although the exact mechanism is not fully understood, CEACAM-20 may promote the proliferation of intestinal epithelial cells (IECs) (9). There is evidence suggesting CEACAM-20 can induce the production of chemokines like interleukin (IL)-8 and stimulate inflammatory responses in colitis and Crohn's disease (6). CEACAM-20 is also thought to act as a physiological substrate for SAP-1 in the intestinal epithelium (10).

1. Tchoupa, A. et al. (2014) J Cell Commun Signal 12:27.
2. Zhang, H. et al. (2013) PLoS ONE 8:e53359.
3. Zebhauser, R. et al. (2005) Genomics 86:566.
4. Beauchemin, N. Arabzadeh, A. (2013) Cancer Metastasis Rev 32(3):643.
5. Kuespert, K. et al. (2006) Curr Opin Cell Biol 18:565.
6. Murata, Y. et al. (2015) PNAS E4264.
7. Obrink, B. (1997) Curr Opin Cell Biol 9:616.
8. Horst, AK. Wagener, C. (2004) Handb Exp Pharmacol 283.
9. Kitamura, Y. et al. (2015) Genes to Cells 20:578.
10. Kotani,  T. et al. (2016) Expert Review of Gastroenterology & Hepatology. 10:1313.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.